TEGA Therapeutics

company

About

TEGA Therapeutics aims to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$269.99K
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Active

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin.

They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$1.49M
TEGA Therapeutics has raised a total of $1.49M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 16, 2020 Grant $0.99M 1 National Science Foundation Detail
Jan 31, 2019 Grant $225K 1 National Science Foundation Detail
Jun 20, 2016 Grant $269.99K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
3
1
TEGA Therapeutics is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant